RecruitingPhase 3NCT06960213
STOP-HAE: A Phase 3 Study of ADX-324 in HAE
STOP-HAE: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of siRNA Targeting of Prekallikrein With ADX-324 in Participants With Hereditary Angioedema
Sponsor
ADARx Pharmaceuticals, Inc.
Enrollment
90 participants
Start Date
Aug 28, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
This study will evaluate the efficacy and safety of ADX-324 in participants with Type 1 or Type 2 hereditary angioedema. The study will also evaluate safety, pharmacokinetics (PK), pharmacodynamics (PD), and health-related quality of life measures.
Eligibility
Min Age: 18 Years
Inclusion Criteria4
- Age ≥18 years at the time of signing informed consent.
- Have a documented diagnosis of HAE-1/HAE-2 (Type I or II)
- Experience ≥1 Investigator-confirmed HAE attack in the first 4 weeks of Screening or ≥2 Investigator-confirmed HAE attacks in 8 weeks of Screening
- Able to use at least one acute therapy to treat HAE attacks (such as a plasma-derived or recombinant C1-INH concentrate or a BK2-receptor antagonist)
Exclusion Criteria9
- Concurrent diagnosis of another form of recurrent angioedema (such as acquired angioedema, HAE with normal C1-INH (previously known as HAE Type III), idiopathic angioedema, or recurrent angioedema associated with urticaria).
- Any clinically significant renal disease
- Any clinically significant hepatic disease
- Have used any of the following for long-term prevention of HAE attacks:
- C1-INH agent (CINRYZE, HAEGARDA, RUCONEST) within 2 weeks prior to Screening.
- Berotralstat (ORLADEYO) within 3 weeks prior to Screening.
- Lanadelumab (TAKHZYRO) within 8 weeks prior to the Screening.
- Androgen use within 12 weeks prior to Screening.
- Received prior treatment with any RNA/DNA-based therapy for HAE or intolerant to any prior RNA/DNA-based therapy for any condition, excluding vaccines.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGADX-324
siRNA duplex oligonucleotide
DRUGPlacebo
saline
Locations(51)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06960213
Related Trials
Rectal Arterial Embolization vs Band Ligation for the Treatment of Internal hemOrrhoidS
NCT075596301 location
Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)
NCT0742849948 locations
Safety Study in Subjects ≥ 12 Years of Age With Hereditary Angioedema Switching to Garadacimab
NCT0680665711 locations
Real-life Ecological Momentary Assessment of Lived Burden in Hereditary AngioEdema
NCT074481811 location
Hemorrhoidal Artery Embolization: Longitudinal Impact On Symptoms (HELIOS)
NCT071796011 location